All News
Falls with Knee Osteoarthritis
A study of adults aged 45-85 yrs shows that knee osteoarthritis (OA) is an independent risk factor for falls, suggesting a greater need for awareness and prevention.
Read Article
NSAID Prescribing Decreasing
Multinational metanalyses of data between 1989 and 2022 shows that NSAID prescriptions have decreased over time, and differs according to geographical locations.
Read Article
With all the new adalimumab biosimilars happening in 2023, where's the pen? Now the FDA has approved an ADA biosimilar, Cyltezo, Autoinjector Pen! https://t.co/yyyPa9d2Ye https://t.co/MuAnfJ0DsB
Links:
Dr. John Cush RheumNow ( View Tweet)
A call for the NIH to address disparities in women’s health research funding. In 1993 Congress mandated NIH include women/minorities in clinical trials. But 30 yrs later, only 11% of NIH budget went to womens diseases https://t.co/8yzUTD1Ufq https://t.co/27W6MnRCFx
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective cross-sectional EMR study from Israel compared GI Dz in 18,598 FM pts vs 36,985 controls. FM significantly assoc w/ IBS (OR 4.61), GERD (OR 2.62), PUD (OR 2.13), celiac Dz(OR 2.08), IBD ; But not w/ GI malignancies https://t.co/mpLb3rE0CB https://t.co/mySSXC5sjA
Links:
Dr. John Cush RheumNow ( View Tweet)
SLE & dsDNA: 3,484 SLE pts (over 37,582 visits) - 29.5% had persistently dsDNA+ & 34% had fluctuating dsDNA.results & both assoc w/ SLE flares (HR 1.56 & 1.46). Doubling of dsDNA assoc w/ 33-36% increased risk of flare (p=0.009) https://t.co/quVlHrfSl3 https://t.co/DkD3h1wV6w
Links:
Dr. John Cush RheumNow ( View Tweet)
Dennis Poddubnyy #RNL2023
MRI sequences for axSpA:
Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression
Semi-axial- T2 STIR
@RheumNow https://t.co/j119qQ0alv https://t.co/pVRO6SfiaI
Links:
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS
- it works but is it different from existing IL-17i?
- appears to work well in TNFi-inadequate responders
- are TNFi-IR pts immunologically different?
#RNL2023 https://t.co/bHboX3Xz6M https://t.co/kCa9MbFdxs
Links:
Dr. John Cush RheumNow ( View Tweet)
A short review from Dr. Deodhar for axSpA at #RNL2023
*prevalence is increasing
*remember the "3,4,5 rule" for MRI eval
*IL17 appear to be as good as TNFi
*may not need XR monitoring
*time will tell if IL17Fi will improve outcomes
https://t.co/fNhZZBmgaS https://t.co/g0g7e3Napl
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Spondyloarthritis Innovations
https://t.co/N7AHcRIwcG https://t.co/eAgdiGTawz
Links:
Dr. John Cush RheumNow ( View Tweet)
Therapeutic Plasma Exchange: Core Curriculum 2023 - Comprehensive, full read overview from American Journal of Kidney diseases & the National Kidney Foundation https://t.co/rmwwj5gol3 https://t.co/XFRZyD6hV4
Links:
Dr. John Cush RheumNow ( View Tweet)
View our infographic from the #LupusEducatorsNetwork and discover how you can apply the concept of #DiseaseModification in #Lupus and #LupusNephritis to help treat patients in your clinical practice #SponsoredbyGSKUSMA
https://t.co/fzspfwarK4 https://t.co/jXNte7f0sY
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: RNL23 Vasculitis Faculty Panel Q&A
RheumNow Live 2023: Robert Spiera, MD, Hospital for Special Surgery Anisha Dua, MD, MPH, Northwestern University, Feinberg School of Medicine Carol Langford, MD, MHS, FACP
https://t.co/4ddqt2tAQ8 https://t.co/KIPp3rePpp
Links:
Dr. John Cush RheumNow ( View Tweet)
SURPASS: SEC vs ADA for axSpA
Outcome: %pts with no radiographic progression
Not benefit- Secukinumab not better than adalimumab
Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! #RNL2023 https://t.co/xlw4nzrwpm https://t.co/dhhLMFQnhI
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: GPA Treatment Choices
https://t.co/MU6gZrgYDr https://t.co/lT1jI9jGGS
Links:
Dr. John Cush RheumNow ( View Tweet)
Colchicine does not work in Hand OA. Danish trial of 100 HOA pts (age 71 yrs) given placebo or COL 0.5 mg bid x 12wk. Finger pain improved –13·9 mm w/ colchicine vs –13·5 mm w/ PBO (NS). More adverse events w/ Colchicine (72% vs 44%) https://t.co/rfANCLcZii https://t.co/OFuMGZSvhm
Links:
Dr. John Cush RheumNow ( View Tweet)
Risk factors for radiographic progression:
Men ♂️
Smoking 🚬
Active inflammation🔥
Blue collar workers 💪
HLA-B27+ 💉
Pre-existing syndesmophyte 🩻
Atul Deodhar at #RNL2023 @RheumNow https://t.co/FcwrDtOG6I https://t.co/AvRpPrg1UK
Links:
Dr. John Cush RheumNow ( View Tweet)
BIOBADASER registry of 3,366 RA/AS/PsA pts on 1,2 bDMARDs saw Remission-related Biologic D/C by 80 pts (2.4%). D/C Factors: short Dz duration (OR: 0.95), no csDMARDs (OR:0.56), shorter use prior bDMARD. Less D/C w/ smoking & ACPA+ https://t.co/iUdU9iI4AZ https://t.co/TknRW6pnJR
Links:
Dr. John Cush RheumNow ( View Tweet)
INBUILD study was an all cause ILD nintedanib RCT (n=663). Subanalysis of 89 RA-ILD pts showed FVC decline (@ 52 wks) was −82.6 mL/yr on NIN vs −199.3 mL/yr on PBO (p=.037). NIN diarrhea in 62%; & AE discontinuation in 24% https://t.co/nWuGx6wjB2 https://t.co/LVwy1Z5TL3
Links:
Dr. John Cush RheumNow ( View Tweet)
Tuesday Night Rheumatology: POD 7: Spondyloarthritis Innovations https://t.co/eDZlgdeWGr
Dr. John Cush RheumNow ( View Tweet)
